iRhythm Technologies Inc
NASDAQ:IRTC

Watchlist Manager
iRhythm Technologies Inc Logo
iRhythm Technologies Inc
NASDAQ:IRTC
Watchlist
Price: 174.4 USD 0.62%
Market Cap: 5.6B USD

iRhythm Technologies Inc
Investor Relations

In the bustling realm of healthcare technology, where innovation meets necessity, iRhythm Technologies Inc. stands as a pivotal player, translating sophisticated algorithms into tangible, life-saving insights. Founded with the mission to redefine how cardiac care is delivered, iRhythm has pioneered its niche through the Zio platform—a sophisticated, wearable patch that monitors heart rhythms with precision. The Zio's elegant design belies its robust function, offering patients the comfort of continuous monitoring while living their daily lives. It gleans crucial data that is then transmitted to iRhythm's cloud-based platform, where advanced data analytics work tirelessly to think like a seasoned cardiologist, initially parsing through millions of heartbeats to identity potential abnormalities.

As healthcare systems worldwide grapple with increasing demands and complexities, iRhythm's business model resonates well with the need for efficiency and effectiveness. The company generates revenue primarily through its patient-centric monitoring services, catering to healthcare providers who seek reliable diagnostic solutions. By billing insurers and healthcare institutions for the analytic results derived from the Zio patch, iRhythm seamlessly integrates into the cardiac care continuum. The blend of cutting-edge technology and strategic partnerships with healthcare providers not only fuels iRhythm's growth but also underscores a broader shift towards personalized and preventive medicine in cardiac care, demonstrating how strategic foresight can align with technical innovation to meet pressing healthcare challenges.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Oct 30, 2025
AI Summary
Q3 2025

Revenue Growth: iRhythm reported Q3 revenue of $192.9 million, up 31% year-over-year, with record performance from both Zio Monitor and Zio AT products.

Margin Expansion: Gross margin improved to 71.1%, up 230 basis points from last year, and adjusted EBITDA margin reached 11.2%, showing strong profitability progress.

Guidance Raised: Full-year 2025 revenue guidance was increased to $735–$740 million, reflecting expected 24–25% YoY growth, and EBITDA margin guidance was also raised.

Cash Flow Positive: iRhythm is generating positive free cash flow ahead of schedule and now expects to be free cash flow positive for the full year 2025.

Innovation & Pipeline: The company filed for FDA clearance of its next-gen Zio MCT device, advanced AI-driven partnerships, and is investing in sleep diagnostics as an adjacent market.

EHR Integration Impact: EHR-integrated accounts see about 25% increased utilization in the first 6 months, with integration seen as a key growth and retention driver.

Channel Expansion: Innovative partner accounts grew from 12 to 18 this quarter, targeting the large undiagnosed arrhythmia population, particularly in asymptomatic and comorbid patients.

Key Financials
Revenue
$192.9 million
Gross Margin
71.1%
Adjusted EBITDA Margin
11.2%
Adjusted Net Loss
$2 million (or $0.06 per share)
Free Cash Flow
$20.0 million (Q3); positive trailing 12-months
Unrestricted Cash and Short-term Investments
$565.2 million
Earnings Call Recording
Other Earnings Calls

Management

Mr. Quentin S. Blackford
President, CEO & Director
No Bio Available
Dr. Minang P. Turakhia M.D., M.S.
Chief Medical & Scientific Officer and Executive VP of Product Innovation
No Bio Available
Mr. Patrick Michael Murphy J.D.
Chief Business & Legal Officer
No Bio Available
Mr. Chad M. Patterson
Chief Commercial Officer
No Bio Available
Mr. Mervin Smith
Executive Vice President of Business Operations
No Bio Available
Mr. Marc Rosenbaum
Senior VP of Finance & Chief Accounting Officer
No Bio Available
Mr. Daniel G. Wilson
Executive VP of Corporate Development & Investor Relations
No Bio Available
Ms. Sumi Shrishrimal
Executive VP & Chief Risk Officer
No Bio Available
Ms. Stephanie Zhadkevich
Director of Investor Relations
No Bio Available

Contacts

Address
CALIFORNIA
San Francisco
699 8Th Street, Suite 600
Contacts
+14156325700.0
www.irhythmtech.com